Clinical trial Recruiting at 4 sites Interventional Ages 6 and up

Testing fatigue levels in patients with spinal muscular atrophy

Official title: Evaluation of the Reproducibility of a Fatigability Test Fitted to Patients With Spinal Muscular Atrophy

Run by Centre Hospitalier Universitaire de Saint Etienne · NCT06562283 · Data updated 2026-11-12

This study is testing new ways to measure fatigue in people with spinal muscular atrophy to help them manage their daily activities better.

Quick facts

Study typeInterventional
Ages6 Years and up
SexAll
Enrollment80 (estimated)
SponsorCentre Hospitalier Universitaire de Saint Etienne
Academic / other
Locations4 sites (Saint-Etienne, France and 3 other locations)
StatusRecruiting
StartedDecember 6, 2024
Main results expectedOctober 2026
Study endsOctober 2026
Registry record updatedMay 6, 2026
Trial IDNCT06562283 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates for this study are patients aged 6 years and older with genetically confirmed spinal muscular atrophy.

Probably not a fit

Patients with other significant neurological diseases or joint deformities that interfere with testing may not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study evaluates a fatigability test specifically designed for patients with spinal muscular atrophy (SMA), a neuromuscular disease characterized by motor neuron degeneration. The research aims to adapt and validate a series of tests, including thumb and grip tests, as well as a quadriceps intermittent fatigue test, to assess muscle fatigue in SMA patients. By understanding fatigue levels, the study seeks to improve the management of daily activities for those affected by SMA, particularly in patients who have received treatment aimed at restoring SMN protein expression. The study includes patients aged 6 years and older who have a confirmed diagnosis of SMA.

Why it matters

Potential benefit: If successful, this study could lead to better assessment and management of fatigue in patients with spinal muscular atrophy, enhancing their quality of life.

How similar studies have gone: While this approach is tailored for SMA, similar fatigue assessments have shown promise in other neuromuscular conditions, indicating potential for success.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Genetically confirmed spinal muscular atrophy
* Age ≥ 6 years
* No orthopaedic surgery in the 6 months prior to inclusion
* Informed consent signed by the patient(s) or parent(s)/legal guardian(s) and assent of the patient
* Affiliated or beneficiary of a health insurance scheme (for inclusion in France)

Exclusion Criteria:

* Other condition that may significantly interfere with the assessment of the SMA and which is clearly unrelated to the disease
* Other associated neurological disease
* Joint deformities that prevent correct and comfortable positioning with the various different measuring devices (thumb-index clamp, handgrip and QIF-test)
* Contraindication to transcranial magnetic stimulation

Where it's running

  • Unités de Myologie et de Médecine du Sport
    Saint-Etienne, France, France
    Recruiting
  • HCL - Hôpital Croix Rousse
    Lyon, France
    Recruiting
  • HFME - Hospices Civils de Lyon
    Lyon, France
    Recruiting
  • Aphp - Hopital Pitie Salpetriere
    Paris, France
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.